Researchers at the Weizmann Institute have initiated the PERIBLOOD clinical trial to evaluate single-cell sequencing as a minimally invasive diagnostic alternative to bone marrow biopsies for myelodysplastic syndromes (MDS). Collaborating with spinout Cliseq and 10x Genomics, the study aims to enroll 1,500 patients worldwide to assess the technology's accuracy in detecting hematopoietic stem and progenitor cell anomalies correlating with MDS. Successful validation could revolutionize MDS diagnostics, sparing patients from painful procedures.